PortfoliosLab logoPortfoliosLab logo
INSM vs. XBI
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

INSM vs. XBI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Insmed Incorporated (INSM) and SPDR S&P Biotech ETF (XBI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, INSM achieves a -43.34% return, which is significantly lower than XBI's 19.74% return. Over the past 10 years, INSM has outperformed XBI with an annualized return of 26.23%, while XBI has yielded a comparatively lower 11.06% annualized return.


INSM

1D
2.93%
1M
-7.19%
YTD
-43.34%
6M
-43.90%
1Y
-3.97%
3Y*
70.31%
5Y*
28.78%
10Y*
26.23%

XBI

1D
3.75%
1M
10.89%
YTD
19.74%
6M
15.96%
1Y
77.88%
3Y*
19.92%
5Y*
1.79%
10Y*
11.06%
*Multi-year figures are annualized to reflect compound growth (CAGR)

INSM vs. XBI - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
INSM
Insmed Incorporated
-43.34%152.09%122.78%55.11%-26.65%-18.17%39.41%82.01%-57.92%135.68%
XBI
SPDR S&P Biotech ETF
19.74%35.89%1.01%7.60%-25.87%-20.45%48.33%32.56%-15.28%43.77%

Correlation

The correlation between INSM and XBI is 0.48, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.48

Correlation (3Y)
Calculated over the trailing 3-year period

0.51

Correlation (5Y)
Calculated over the trailing 5-year period

0.62

Correlation (10Y)
Calculated over the trailing 10-year period

0.63

Correlation (All Time)
Calculated using the full available price history since Feb 6, 2006

0.50

The correlation between INSM and XBI shifts across timeframes, from 0.48 (1 year) to 0.63 (10 years), reflecting how their relationship changes across market environments.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

INSM vs. XBI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

INSM
INSM Risk / Return Rank: 3939
Overall Rank
INSM Sharpe Ratio Rank: 3939
Sharpe Ratio Rank
INSM Sortino Ratio Rank: 3838
Sortino Ratio Rank
INSM Omega Ratio Rank: 3838
Omega Ratio Rank
INSM Calmar Ratio Rank: 4040
Calmar Ratio Rank
INSM Martin Ratio Rank: 3939
Martin Ratio Rank

XBI
XBI Risk / Return Rank: 9090
Overall Rank
XBI Sharpe Ratio Rank: 9191
Sharpe Ratio Rank
XBI Sortino Ratio Rank: 8888
Sortino Ratio Rank
XBI Omega Ratio Rank: 8181
Omega Ratio Rank
XBI Calmar Ratio Rank: 9696
Calmar Ratio Rank
XBI Martin Ratio Rank: 9393
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

INSM vs. XBI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Insmed Incorporated (INSM) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


INSMXBIDifference
Sharpe ratioReturn per unit of total volatility

-3.03

Sortino ratioReturn per unit of downside risk

-3.57

Omega ratioGain probability vs. loss probability

1.04

1.46

-0.42

Calmar ratioReturn relative to maximum drawdown

-0.07

8.05

-8.12

Martin ratioReturn relative to average drawdown

-0.16

23.79

-23.95

INSM vs. XBI - Sharpe Ratio Comparison

The current INSM Sharpe Ratio is -0.08, which is lower than the XBI Sharpe Ratio of 2.96. The chart below compares the historical Sharpe Ratios of INSM and XBI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

INSM vs. XBI - Drawdown Comparison

The maximum INSM drawdown since its inception was -98.65%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for INSM and XBI.


Loading charts...

Drawdown Indicators


INSMXBIDifference

Max Drawdown

Largest peak-to-trough decline

-98.65%

-63.89%

-34.76%

Max Drawdown (1Y)

Largest decline over 1 year

-56.54%

-9.72%

-46.82%

Max Drawdown (3Y)

Largest decline over 3 years

-56.54%

-32.99%

-23.55%

Max Drawdown (5Y)

Largest decline over 5 years

-56.54%

-54.71%

-1.83%

Max Drawdown (10Y)

Largest decline over 10 years

-64.84%

-63.89%

-0.95%

Current Drawdown

Current decline from peak

-53.36%

-15.61%

-37.75%

Average Drawdown

Average peak-to-trough decline

-86.05%

-20.93%

-65.12%

Ulcer Index

Depth and duration of drawdowns from previous peaks

24.87%

3.28%

+21.59%

Volatility

INSM vs. XBI - Volatility Comparison

Insmed Incorporated (INSM) has a higher volatility of 17.30% compared to SPDR S&P Biotech ETF (XBI) at 9.97%. This indicates that INSM's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


INSMXBIDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.30%

9.97%

+7.33%

Volatility (6M)

Calculated over the trailing 6-month period

46.26%

21.32%

+24.94%

Volatility (1Y)

Calculated over the trailing 1-year period

52.19%

26.52%

+25.67%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

72.88%

32.30%

+40.58%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

78.49%

32.04%

+46.45%

Dividends

INSM vs. XBI - Dividend Comparison

INSM has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.40%.


PositionTTM20252024202320222021202020192018201720162015
INSM
Insmed Incorporated
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
XBI
SPDR S&P Biotech ETF
0.40%0.37%0.15%0.02%0.00%0.04%0.20%0.00%0.28%0.24%0.26%0.61%

Frequently Asked Questions


INSM and XBI have a correlation of 0.48, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

INSM has higher volatility (17.30%) compared to XBI (9.97%). In terms of maximum drawdown, INSM dropped -98.65% vs XBI's -63.89%.

XBI currently has the higher Sharpe Ratio (2.96 vs -0.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for INSM and XBI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer